The meta-analysis showed (Fig. 8) that immune checkpoint inhibitors versus chemotherapy had similar effects in treating NSCLC patients having KRAS wild-type for the OS (HR, 0.89; 95% CI, 0.68–1.17). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.